The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of prior definitive therapy on survival outcomes in men with new hormone-sensitive metastatic prostate cancer (mHSPC).
 
Anitha Alex
No Relationships to Disclose
 
David D. Stenehjem
No Relationships to Disclose
 
Przemyslaw Twardowski
No Relationships to Disclose
 
Heather H. Cheng
No Relationships to Disclose
 
David Michael Gill
No Relationships to Disclose
 
Tyler Howard Buckley
No Relationships to Disclose
 
Shiven B. Patel
No Relationships to Disclose
 
Elizabeth Riley Kessler
No Relationships to Disclose
 
Namita Chittoria
No Relationships to Disclose
 
Aarati Poudel
No Relationships to Disclose
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Novartis; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Research Funding - Astellas Pharma; Exelixis; Novartis; Pfizer
 
Neeraj Agarwal
Research Funding - amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)